Deep Track Capital, LP
Q1 2022 13F-HR Holdings
Net value change ($000)
+142,880
(10.1%)
New positions
11
Sold out positions
11
Turnover %
19.5%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2021
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ALNY | 75,712 | NEW |
| FATE | 53,081 | 217.0% |
| NVCR | 41,556 | 100.6% |
| MDGL | 34,752 | 82.0% |
| AGEN | 34,436 | NEW |
| Global Blood Therapeutics, Inc. | 21,294 | 36.4% |
| KURA | 19,165 | 53.7% |
| JAZZ | 16,789 | 26.4% |
| Forma Therapeutics Holdings, Inc. | 15,435 | NEW |
| BCYC | 14,484 | 21.6% |
Top Reduces (Value $000, Stocks/ETFs)
| RNAM | -23,770 | -100.0% |
| CRNX | -20,138 | -37.3% |
| Karuna Therapeutics, Inc. | -17,056 | -100.0% |
| Verve Therapeutics, Inc. | -16,100 | -87.3% |
| PTGX | -14,421 | -100.0% |
| Sierra Oncology, Inc. | -13,209 | -100.0% |
| BEAM | -12,020 | -21.5% |
| ATRA | -11,820 | -100.0% |
| ASND | -10,762 | -100.0% |
| Gritstone bio, Inc. | -10,484 | -46.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
11,597
(0.7% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|